AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36830825 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS.
Number of subjects: 23
Study 36831483 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical fimbriectomy (RF)
Number of subjects: 121
Study 36831483 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical fimbriectomy (RF) followed by delayed oophorectomy
Number of subjects: 121
Study 36831483 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed oophorectomy
Number of subjects: 121
Study 36831516 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided localization (WGL)
Number of subjects: 0
Study 36831516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 0
Study 36831516 — intervention group
Group type: COMPARATOR
Intervention: Radioactive techniques
Number of subjects: 0
Study 36831516 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-free localization
Number of subjects: 0
Study 36831658 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 0
Study 36831658 — intervention group
Group type: COMPARATOR
Intervention: Conventional supportive care
Number of subjects: 0
Study 36831709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure (LBPP) Treadmill Training
Number of subjects: 9
Study 36832093 — intervention group
Group type: EXPERIMENTAL
Intervention: PRRT
Number of subjects: 39
Study 36832093 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SRETV_WB and ΔSRETV_WB
Number of subjects: 39
Study 36833192 — intervention group
Group type: EXPERIMENTAL
Intervention: CAH-X treatment
Number of subjects: 0
Study 36833293 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) expanded to trio sequencing
Number of subjects: 1
Study 36833293 — intervention group
Group type: COMPARATOR
Intervention: Molecular karyotyping
Number of subjects: 1
Study 36833293 — intervention group
Group type: EXPERIMENTAL
Intervention: Trio WES
Number of subjects: 1
Study 36833589 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week high intensity online physical exercise intervention combined with online group meetings and supported by an activity watch
Number of subjects: 19
Study 36833793 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized computerized cognitive training (CCT) for 8 weeks
Number of subjects: 73
Study 36834170 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)-guided laparoscopic/robotic pelvic lymphadenectomy
Number of subjects: 0
Study 36834170 — intervention group
Group type: COMPARATOR
Intervention: Standard systematic lymphadenectomy
Number of subjects: 0
Study 36834268 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VeNS
Number of subjects: 60
Study 36834268 — intervention group
Group type: COMPARATOR
Intervention: Sham VeNS
Number of subjects: 60
Study 36834329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS) programme
Number of subjects: 308
Study 36834329 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 308
Study 36834367 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injection through a transforaminal approach (ESI TF)
Number of subjects: 0
Study 36834367 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36836101 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM-HFpEF patients
Number of subjects: 911
Study 36836101 — intervention group
Group type: COMPARATOR
Intervention: DCM-HFrEF patients
Number of subjects: 911
Study 36839324 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones and enterolignans dietary intake assessment through 24 h and 48 h dietary recalls
Number of subjects: 0
Study 36839324 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine and plasma samples analysis for genistein, daidzein, equol, and enterolactone
Number of subjects: 0
Study 36839882 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared photoimmunotherapy (NIR-PIT)
Number of subjects: 0
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg QD and Sorafenib 200 mg BID (intermittent schedule)
Number of subjects: 43
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangiocarcinomas (intermittent schedule)
Number of subjects: 43
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological adenocarcinomas (intermittent schedule)
Number of subjects: 43
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing schedules
Number of subjects: 43
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: EVE 10 mg QD and SOR 400 mg BID (intermittent schedules)
Number of subjects: 43
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reductions
Number of subjects: 43
Study 36840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicities
Number of subjects: 43
Study 36840825 — intervention group
Group type: EXPERIMENTAL
Intervention: Early RRT initiation strategy
Number of subjects: 112
Study 36840825 — intervention group
Group type: COMPARATOR
Intervention: Delayed RRT initiation strategy
Number of subjects: 112
Study 36840825 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 112
Study 36840825 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of septic shock
Number of subjects: 112
Study 36840825 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure
Number of subjects: 112
Study 36840825 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam trough concentration above 4 times the MIC
Number of subjects: 112
Study 36841085 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetic retinopathy (DR)
Number of subjects: 1758
Study 36841085 — intervention group
Group type: COMPARATOR
Intervention: No diabetic retinopathy (DR)
Number of subjects: 1758
Study 36841141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Number of subjects: 210
Study 36841318 — intervention group
Group type: EXPERIMENTAL
Intervention: Goreisan at a dose of 7.5 g daily on top of usual care
Number of subjects: 2192
Study 36841318 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2192
Study 36841351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemiralisib
Number of subjects: 5
Study 36841360 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic treatment eligibility assessment
Number of subjects: 97
Study 36841360 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids (SCS) use
Number of subjects: 97
Study 36841360 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids (OCS) use
Number of subjects: 97
Study 36841360 — intervention group
Group type: COMPARATOR
Intervention: Asthma control assessment
Number of subjects: 97
Study 36841360 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life (HRQoL) assessment using SGRQ
Number of subjects: 97
Study 36841360 — intervention group
Group type: COMPARATOR
Intervention: Symptom burden assessment
Number of subjects: 97
Study 36841444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Profile (LGIP)
Number of subjects: 25
Study 36841444 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index Profile (HGIP)
Number of subjects: 25
Study 36841502 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (Moreau or Moscow strains)
Number of subjects: 264
Study 36841502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 36841502 — intervention group
Group type: EXPERIMENTAL
Intervention: Moreau strain of BCG vaccine
Number of subjects: 264
Study 36841502 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 264
Study 36841506 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (FOS+GOS)
Number of subjects: 24
Study 36841506 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study 36841540 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 1 year)
Number of subjects: 35
Study 36841540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 36841633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filters (VCFs) implanted in 1421 patients
Number of subjects: 1429
Study 36841672 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approaches for TP53 mutated MDS and AML patients
Number of subjects: 0
Study 36841672 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal testing strategies for TP53 mutations
Number of subjects: 0
Study 36841723 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 1191
Study 36841723 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 1191
Study 36841758 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1594a·HCl
Number of subjects: 0
Study 36841758 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1594a·succinate
Number of subjects: 0
Study 36841758 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1594a·HCl and DS-1594a·succinate
Number of subjects: 0
Study 36841758 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1594a
Number of subjects: 0
Study 36841758 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine
Number of subjects: 0
Study 36841762 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/day
Number of subjects: 195
Study 36841762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (exercise + liraglutide)
Number of subjects: 195
Study 36841762 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous exercise
Number of subjects: 195
Study 36841762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 36841770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ving Tsun sticking-hand training
Number of subjects: 33
Study 36841770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 36841773 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transspinal stimulation
Number of subjects: 45
Study 36841773 — intervention group
Group type: COMPARATOR
Intervention: Sham transspinal stimulation
Number of subjects: 45
Study 36841790 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time)
Number of subjects: 220
Study 36841790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 220
Study 36841794 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine combined with pregabalin
Number of subjects: 0
Study 36841794 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and placebo capsules
Number of subjects: 0
Study 36841796 — intervention group
Group type: EXPERIMENTAL
Intervention: EOB-MRI
Number of subjects: 101
Study 36841886 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss intervention (Loss group)
Number of subjects: 305
Study 36841886 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Stability intervention (Stability group)
Number of subjects: 305
Study 36841886 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy (Control group)
Number of subjects: 305
Study 36841886 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking cessation
Number of subjects: 305
Study 36841997 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure (Group A) - skin closed with interrupted polypropylene sutures
Number of subjects: 50
Study 36841997 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure (Group B) - wound dressed with saline-soaked gauze and allowed to heal by secondary intention
Number of subjects: 50
Study 36842024 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff exercises
Number of subjects: 20
Study 36842024 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-Somersault exercises
Number of subjects: 20
Study 36842024 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 36842439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (65 Gy in 54 fractions, given twice daily with an interfractional time interval of at least 6 h)
Number of subjects: 144
Study 36842439 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (60 Gy in 27 fractions, given once a day)
Number of subjects: 144
Study 36842439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 144
Study 36842439 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation
Number of subjects: 144
Study 36842446 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutivacaftor 150 mg once daily
Number of subjects: 47
Study 36842446 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutivacaftor 250 mg once daily
Number of subjects: 47
Study 36842446 — intervention group
Group type: COMPARATOR
Intervention: Elexacaftor-tezacaftor-ivacaftor (control group)
Number of subjects: 47
Study 36842451 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fructose-containing sugars
Number of subjects: 10357
Study 36842451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) at high doses (≥20%E or 100 g/d)
Number of subjects: 10357
Study 36842451 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of sugars
Number of subjects: 10357
Study 36842451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits at lower doses (≤10%E or 50 g/d)
Number of subjects: 10357
Study 36842451 — intervention group
Group type: EXPERIMENTAL
Intervention: Other food sources of sugars
Number of subjects: 10357
Study 36842486 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring-based HF disease management (n=159)
Number of subjects: 212
Study 36842486 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based HF disease management (n=53)
Number of subjects: 212
Study 36842489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 30
Study 36842489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36842666 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model combining CT and RD images
Number of subjects: 314
Study 36842666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted deep learning model using CT and RD weights
Number of subjects: 314
Study 36842675 — intervention group
Group type: EXPERIMENTAL
Intervention: High IFABP group
Number of subjects: 50
Study 36842675 — intervention group
Group type: COMPARATOR
Intervention: Low IFABP group
Number of subjects: 50
Study 36842675 — intervention group
Group type: EXPERIMENTAL
Intervention: IFABP
Number of subjects: 50
Study 36842754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed protein
Number of subjects: 19
Study 36842754 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed protein
Number of subjects: 19
Study 36842841 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma amyloid beta ratio (AβR) increase from preoperative to postoperative Day 1
Number of subjects: 100
Study 36842841 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in plasma AβR
Number of subjects: 100
Study 36842849 — intervention group
Group type: EXPERIMENTAL
Intervention: relmacabtagene autoleucel (relma-cel) infusion after lymphodepletion chemotherapy
Number of subjects: 68
Study 36842886 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 (90 µg single dose)
Number of subjects: 52
Study 36842886 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 (two 45 µg doses 28 days apart)
Number of subjects: 52
Study 36842886 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 (both cohorts)
Number of subjects: 52
Study 36842956 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate metrics
Number of subjects: 104
Study 36842956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber RDA
Number of subjects: 104
Study 36842956 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall carbohydrate quality measures
Number of subjects: 104
Study 36842964 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tandospirone (60 mg/d)
Number of subjects: 274
Study 36842964 — intervention group
Group type: COMPARATOR
Intervention: Low-dose tandospirone (30 mg/d)
Number of subjects: 274
Study 36843239 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy for 3 months
Number of subjects: 220
Study 36843256 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 0
Study 36843256 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC901
Number of subjects: 0
Study 36843368 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial trigeminal nerve blocks (0.5% ropivacaine with epi 1:200,000)
Number of subjects: 46
Study 36843368 — intervention group
Group type: COMPARATOR
Intervention: Placebo/sham (0.9% normal saline)
Number of subjects: 46
Study 36843446 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention based on social cognitive theory (SCT) delivered through the Internet using e-learning approaches
Number of subjects: 0
Study 36843567 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom model
Number of subjects: 66
Study 36843975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation 1000 IU
Number of subjects: 101
Study 36843975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation 200 IU
Number of subjects: 101
Study 36843975 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study 36844198 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTS-c
Number of subjects: 142
Study 36844198 — intervention group
Group type: EXPERIMENTAL
Intervention: Romo1
Number of subjects: 142
Study 36844736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus trastuzumab
Number of subjects: 0
Study 36844736 — intervention group
Group type: COMPARATOR
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 0
Study 36844740 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn device combining PPG and ECG
Number of subjects: 30
Study 36844740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent 30 s Lead I ECG
Number of subjects: 30
Study 36845050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketone ester (395 mg/kg)
Number of subjects: 12
Study 36845050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 36845426 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous HFAC at 30 kHz
Number of subjects: 0
Study 36845426 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 36845633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of preoperative radiotherapy (6 to 14 Gy)
Number of subjects: 0
Study 36845633 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment (maximal safe resection and postoperative chemoradiotherapy with 60 Gy/30 fr and concurrent/adjuvant temozolomide)
Number of subjects: 0
Study 36845654 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency WB-EMS strength training (HFG)
Number of subjects: 24
Study 36845654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency WB-EMS aerobic training (LFG)
Number of subjects: 24
Study 36845654 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (CG)
Number of subjects: 24
Study 36845705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) and escalating doses of IL-2 (6,000 or 60,000 or 600,000 IU/kg IV bolus every 8 hours up to 14 doses per cycle)
Number of subjects: 10
Study 36845705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2 therapy in combination with pembrolizumab
Number of subjects: 10
Study 36846138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 344
Study 36846138 — intervention group
Group type: COMPARATOR
Intervention: Low-dose atorvastatin
Number of subjects: 344
Study 36846414 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR-QL questionnaire
Number of subjects: 1173
Study 36846600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lungs from DCD donors
Number of subjects: 0
Study 36846600 — intervention group
Group type: COMPARATOR
Intervention: Lungs from DBD donors
Number of subjects: 0
Study 36846961 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved CFR and low IMR (group 1)
Number of subjects: 375
Study 36846961 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved CFR and elevated IMR (group 2)
Number of subjects: 375
Study 36846961 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed CFR and low IMR (group 3)
Number of subjects: 375
Study 36846961 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed CFR and elevated IMR (group 4)
Number of subjects: 375
Study 36846982 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on sex, previous history of intracranial aneurysm/aSAH, and older age score
Number of subjects: 499
Study 36846982 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of new intracranial aneurysms
Number of subjects: 499
Study 36847281 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Latarjet procedure on the dominant side
Number of subjects: 133
Study 36847281 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Latarjet procedure on the nondominant side
Number of subjects: 133
Study 36847281 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 133
Study 36847333 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily blueberry consumption for 12 weeks
Number of subjects: 0
Study 36847333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36847750 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER; 100 to 600 mg/day)
Number of subjects: 1354
Study 36847750 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER)
Number of subjects: 1354
Study 36847750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1354
Study 36847909 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 22
Study 36847909 — intervention group
Group type: COMPARATOR
Intervention: Diode laser
Number of subjects: 22